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Human immunodeficiency virus (HIV)-infected children are at
risk of developing several types of renal diseases, including
HIV-associated nephropathy (HIVAN), which is usually seen
during late stages of infection in children with a high viral
load. This disease is defined by the presence of proteinuria
associated with mesangial hyperplasia and/or global–focal
segmental glomerulosclerosis combined with microcystic
transformation of the renal tubules. Because HIVAN can have
an insidious clinical onset, renal biopsy is the only definitive
way of establishing a diagnosis. Given the risk of performing
this procedure in HIV-infected children with other AIDS-
defining illness, we sought to identify informative biomarkers
such as growth factors in the urine of 55 HIV-infected
children that might be predictive of the extent and activity of
the renal lesions characteristic of HIVAN. We found that the
levels of epidermal growth factor were lower in the urine of
children with renal disease, whereas levels of fibroblast
growth factor-2 and metalloproteinase-2 were higher as
compared with those levels in infected children without
renal disease. Similar changes were observed in HIV-Tg26
mice correlating with the progression of renal disease in this
model of HIVAN. Our findings suggest that this urinary
growth factor profile may be useful in facilitating the
diagnosis of HIV-infected children at risk of developing
HIVAN when interpreted in the appropriate clinical setting.
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Childhood human immunodeficiency virus (HIV)-associated
nephropathy (HIVAN) is a renal disease (RD) defined
by the presence of persistent proteinuria associated
with mesangial hyperplasia and/or global–focal segmental
glomerulosclerosis in combination with microcystic
transformation of renal tubules and rapid progression to
chronic renal failure.1–3 It is usually seen during the late
stages of HIV infection in children with a high viral load.
Black children show a unique susceptibility to develop
this RD, and if the US data from the pre-HAART (highly
active antiretroviral therapy) era were extrapolated to Africa,4
we speculate that approximately 300,000 children without
access to antiretroviral therapy could develop HIVAN. In
addition, HIV-infected children can develop other RD or
tubular toxicity secondary to HAART and other drugs.1–3
Thus, to prevent the severe complications associated with
these RD, it is necessary to perform an early diagnosis, and
the only way of establishing a definitive diagnosis of HIVAN
is to make a renal biopsy. Given the risk of performing this
procedure in HIV-infected children, it is necessary to find
new biomarkers to identify children at high risk of
developing HIVAN.
In a recent study using a proteomic approach, we were
unable to identify a single urine protein biomarker to identify
children with biopsy-proven HIVAN.5 Here, we sought to
determine whether growth factors released into the urine of
children with HIV-RD reflect the extent and activity of the
renal lesions characteristic of this disease. This approach is
based on earlier studies showing a progressive accumulation
of heparin-binding growth factors in correlation with the
development of the renal microcystic tubular lesions that are
a characteristic feature of childhood HIVAN.6–9 We found
elevated urine levels of fibroblast growth factor-2 (FGF-2)
and matrix metalloproteinase-2 (MMP-2), in association
with reduced urine levels of epidermal growth factor (EGF)
in children with HIV-RD. As these growth factors are
involved in the processes of renal tubular regeneration and
cyst formation,10–20 our findings suggest that this urine
profile might be useful in identifying children undergoing the
tubular interstitial and microcystic lesions characteristic of
HIVAN.
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RESULTS
Renal tubular injury in HIV-RD
As shown in Figure 1, we found elevated levels of cystatin C,
g-glutamyl transpeptidase (g-GT), and lysozyme in a group
of children with established HIV-RD. The urinary lysozyme
levels were also significantly elevated in HIV-infected children
with trace proteinuria (Po0.05) (Figure 1a), suggesting that
the brush border of renal proximal tubular cells was injured
in these patients. On the basis of these findings, we
hypothesized that the urinary excretion of EGF, which is
synthesized mainly by renal epithelial cells, would be reduced
in children with HIVAN.
Decreased urinary levels of EGF in children with HIV-RD
To determine the urinary levels of EGF in HIV-positive and
-negative children of different ages without RD, EGF was
measured in the following groups of control children: (1)o2
years of age, with functionally immature kidneys with respect
to glomerular function; (2) 2–12 years of age, with
functionally mature pre-pubescent kidneys; and (3) 412
years, with mature pubescent kidneys. No significant
differences in urinary EGF levels were found between HIV-
positive or -negative children of similar age without RD (data
not shown). However, children o2 years showed the highest
urinary EGF levels when compared with all other age control
groups (Table 1).
The urinary EGF concentration was significantly lower in
children 42 years with biopsy-proven HIVAN (n¼ 6), when
compared with their corresponding age-matched HIV
controls and trace proteinuria groups (Figure 2a, Po0.0001
and Figure 2b, Po0.05). Moreover, two children o2 years
with HIVAN also showed a reduction in their urinary EGF
levels of approximately 32 and 45%, relative to the mean
values of age-matched controls. These changes were similar
to the low values reported in children of similar age with
congenital obstructive nephropathy.10 In summary, only one
child within six children 42 years with biopsy-proven
HIVAN showed normal urinary EGF levels.
Growth-promoting activity of EGF in urine samples harvested
from HIV-infected children
As shown in Figure 2c, urine samples harvested from HIV-
infected children with and without RD stimulated the growth
of cultured renal tubular epithelial CV-1 cells by an average
88 and 145% (Po0.001), respectively, when compared with
the cells exposed to control media containing 1% fetal bovine
serum. Moreover, urine samples harvested from children with
HIVAN increased the growth of CV-1 cells by an average of
57.6% when compared with the control samples (Po0.05)
(Figure 2c). EGF-neutralizing antibodies were able to
suppress the growth-promoting activity of urine samples
harvested from the HIV-infected controls (HIV-C; Po0.001)
and trace proteinuria (HIV-T; Po0.01) groups, respectively
(Figure 2d and e). In contrast, EGF antibodies failed to exert
a complete growth inhibition of CV-1 cells exposed to urine
supernatants harvested from children with HIVAN (P40.05)
(Figure 2f). These data suggest that other growth factors that
are present in the urine of children with HIVAN (that is,
FGF-2), may act in synergy with EGF to enhance the
proliferation of tubular epithelial cells in these patients.6–9
Increased urinary FGF-2 in children with HIVAN
Children o2 years show the highest urinary levels of FGF-2,
but these changes were not statistically significant when
compared with all other age control groups (Table 1). All
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Figure 1 | Increased levels of urinary biomarkers of renal
tubular injury in HIV-infected children with renal disease.
Panels a–d show mean±s.e.m. values for cystatin C (a), g-
glutamyl-transpeptidase (g-GT) (b), lysozyme (c), and alkaline
phosphatase (AP) (d) in urine samples harvested simultaneously
from HIV-infected children without proteinuria (HIV-C; n¼ 10);
trace proteinuria (HIV-T; n¼ 8); and established renal disease (HIV-
RD; n¼ 9). Urine values were expressed as a urinary creatinine
(UCR) ratio. P-values less than 0.05 were considered statistically
significant. (* and # indicate a Po0.05; ** indicates a Po0.0001
when compared with HIV-C, and HIV-T groups, respectively).
Table 1 | Average urinary levels of EGF, FGF-2, and MMP-2 in
children without renal disease
Control group age (years)*
Biomarker o2 2–12 412
EGF/UCR (pg/mg) 96,045±7751* 40,238±2967 29,485±6468
FGF-2/UCR (pg/mg) 5.86±1.32 4.9±1.14 2.33±0.39
MMP-2 (ng/mg) 2.93±0.86 0.93±0.23 1.10±0.22
EGF, epidermal growth factor; FGF-2, fibroblast growth factor-2; MMP-2, matrix
metalloproteinase-2; UCR, urinary creatinine ratio.
All values are expressed as the mean±s.e. of the mean, and expressed as a ratio of
the urinary creatinine value. (n=8–24 children per group). Non-parametric analysis of
variance *Po0.05 and 0.001 when compared with the EGF groups of children of
2–12 years and 412 years of age, respectively. No statistically significant differences
were found between the groups of children 42 years of age for EGF, FGF-2, and
MMP-2 (P=0.0648; 0.1716; and 0.5668, respectively).
208 Kidney International (2009) 76, 207–214
o r i g i n a l a r t i c l e A´A Soler-Garcı´a et al.: Urinary EGF, FGF-2, and MMP-2 levels in HIVAN
children 42 years with biopsy-proven HIVAN (n¼ 6)
showed high abnormal urinary FGF-2 levels, when compared
with their corresponding age-matched HIV controls and
trace proteinuria groups (Figure 3a and b). Similarly, in both
children o2 years with HIVAN, the urinary FGF-2 levels
140
120
300
250
200
150
160
140
120
100
100
100
80
60
40
20
0
%
 C
ha
ng
e 
EG
F/
UC
R
(pg
/m
g)
EG
F/
UC
R 
(pg
/m
g)
Co
ntr
ol
Co
ntr
ol
LV
L-H
IV
HV
L-H
IV
HIV
-
C
Co
ntr
ol
HIV
-
C
HIV
-
C +
 EG
F a
b
Co
ntr
ol
HIV
-
T
HIV
-
T +
 EG
F a
b
Co
ntr
ol
HIV
AN
 + 
EG
F a
b
HIV
AN
HIV
AN
HIV
AN
HIV
AN
HIV
-
T
HIV
-
C
60,000
50,000
40,000
30,000
20,000
10,000
0
**
***
**
**
*
* *
#
**
#
##
##
G
ro
w
th
 a
ct
iv
ity
 a
s 
%
 c
on
tro
l
G
ro
w
th
 a
ct
iv
ity
 a
s 
%
 c
on
tro
l
160
140
120
100
G
ro
w
th
 a
ct
iv
ity
 a
s 
%
 c
on
tro
l
160
140
120
100
G
ro
w
th
 a
ct
iv
ity
 a
s 
%
 c
on
tro
l
Figure 2 | Decrease EGF levels in the urine of HIV-infected
children 42 years of age with HIVAN. Panel a shows the
urinary EGF levels in controls (HIV-negative children without renal
disease; n¼ 8); HIV-infected children without renal disease and low
viral load (o5000 copies/ml; HIV-LVC, n¼ 15); HIV-infected children
without renal disease and high viral load (410,000 copies/ml; HIV-
HVC, n¼ 26); and children with biopsy-proven HIVAN (n¼ 6). Urine
values are expressed as % change relative to the control group.
Panel b shows changes in urinary EGF levels in HIV-infected children
42 years of age without proteinuria (HIV-C; n¼ 10); trace
proteinuria (HIV-T; n¼ 8); and biopsy-proven HIVAN (n¼ 6). Panels
c–f show the urinary EGF-induced growth promoting activity in
cultured CV-1 renal tubular epithelial cells. CV-1 cells were exposed
for 96 h to urine samples harvested from HIV-infected children
without proteinuria (HIV-C), trace proteinuria (HIV-T), and HIVAN as
described in the Materials and Methods setion. CV-1 cells exposed
to 1% FBS media were used as controls. These experiments were
made in the presence or absence of an anti-EGF-neutralizing
antibodies. Bars represent the mean±s.e.m. P-values less than 0.05
were considered statistically significant. (* and # indicate a Po0.05;
** and ## indicate a Po0.001; *** indicates Po0.0001 when
compared to all other groups. when compared with the control
alone and cells exposed to urine, respectively). All the experiments
were performed in triplicate.
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Figure 3 | Increase FGF-2 and metalloproteinase 2 (MMP-2)
levels in the urine of HIV-infected children 42 years of age
with HIVAN. Panels a and c show changes in FGF-2 and MMP-2
urine values corresponding to controls (HIV-negative children
without renal disease; n¼ 8); HIV-infected children without renal
disease and low viral load (o5000 copies/ml; HIV-LVC, n¼ 15);
HIV-infected children without renal disease and high viral load
(410,000 copies/ml; (HIV-HVC, n¼ 26); and children42 years of age
with biopsy-proven HIVAN (n¼ 6). Urine values are expressed as a %
change relative to the control group. Panels b and d show changes
in FGF-2 (b) and MMP-2 (d) urine values in HIV-infected children 42
years of age without proteinuria (HIV-C; n¼ 10); HIV-infected
children with trace proteinuria (HIV-T; n¼ 8); and HIV-infected
children 42 years of age with biopsy-proven HIVAN (n¼ 6). Panel e
shows urinary levels of MMP-9 (e) in HIV-infected children of all ages
without proteinuria (HIV-C; n¼ 10); trace proteinuria (HIV-T; n¼ 8); or
established renal disease (HIV-RD; n¼ 9). This last group included
seven children of all ages with biopsy-proven HIVAN. P-values less
than 0.05 were considered statistically significant. (* and # indicate a
Po0.05 when compared with HIV-C, and HIV-T groups, respectively;
** and *** indicate Po0.001 and Po0.0001, respectively, when
compared to all the other groups).
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increased by an average of 2.5- to 11-fold over their age-
matched controls, and above the normal values reported for
children of similar age.18
Increase urinary MMP-2 in children with HIVAN
Children o2 years showed the highest urinary levels of
MMP-2, when compared with all other age control groups
(Table 1). MMP-2 was elevated in the urine of children 42
years with biopsy-proven HIVAN (n¼ 6) in comparison with
their respective age-matched control (Po0.001) and trace
proteinuria (Po0.05) groups (Figure 3c and d). In a similar
way, urinary MMP-2 increased in both children o2 years
with HIVAN by an average of 0.5- to 68-fold over their age-
matched controls and above the normal values reported by
others.13 Finally, no significant differences in the urinary
levels of MMP-9 were detected between HIV-infected
children in the control, trace proteinuria, and HIVAN
groups, respectively (40.05) (Figure 3e). In summary, all
children with biopsy-proven HIVAN showed abnormally
elevated urinary levels of both MMP-2 and FGF-2 relative to
their corresponding age-matched control groups.
Gelatin zymographic analysis
Figure 4a shows a representative gelatin zymographic analysis
of urine samples harvested from HIV-infected children with
and without RD, including seven children with HIVAN. The
collagenolytic activity in these urine samples was inhibited in
the presence of 20 mM 1, 10-phenanthroline, confirming the
presence of metalloproteinases activity (Figure 4a). MMP-2
was detected as 72 and 64 kDa collagenolytic bands
corresponding to the latent and active forms of this
metalloproteinase.13 The activity of MMP-2 was increased
in the urine of children with established RD relative
to the control group (Figure 4b). MMP-9 was detected as
92 and 82 kDa collagenolytic bands corresponding to the
latent and active forms of this metalloproteinase (Figure 4c).
HIV-infected children with trace proteinuria and established
RD showed an increased urinary MMP-9 activity; however,
these changes were not statistically significant (Figure 4c).
Progressive changes in urinary EGF, FGF-2, and MMP-2 levels
in a child with biopsy-proven HIVAN
As shown in Figure 5, the urinary levels of EGF in a child
with HIVAN increased in correlation with the recovery of
renal function in response to antiretroviral therapy (Figure 5a
and b). In contrast, the urinary concentration of FGF-2 and
MMP-2 decreased in correlation with the recovery of renal
function. However, the urinary levels of EGF, FGF-2, and
MMP-2 remained within abnormal values throughout the
follow-up period (Figure 5c and d).
Changes in EGF and MMPs expression in correlation with the
development of RD in HIV-Tg26 mice
As shown in Figure 6, representative urine samples harvested
from wild-type (WT) littermate control mice showed an
increased EGF-binding activity when compared with the
samples corresponding HIV-Tg mice with severe RD (Figure
6a). When adjusted for the urinary creatinine concentration,
EGF activity was approximately fivefold greater in the urine
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incubation in the presence of 20 mM 1,10-phenanthroline, an MMP
inhibitor. Panel a shows urinary zymograms of HIV-infected
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mean±s.e.m. collagenolytic activity values corresponding to
MMP-2 (b) and MMP-9 (c). The results are expressed in arbitrary
optical density units (OD) as a urinary creatinine (UCR) ratio (OD/
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Figure 5 | Progressive changes in the urinary biomarker
profile in a child with biopsy-proven HIVAN. Progressive
changes in serum creatinine (SCr) and blood urea nitrogen (BUN)
(a), EGF (b), FGF-2, (c) and MMP-2 (d) in urine samples collected
from a child with biopsy-proven HIVAN treated successfully with
antiretroviral therapy. Dotted lines indicate the expected average
normal values for each measurement.
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of WT mice relative to the urine of HIV-Tg mice with RD. In
support of these findings, northern blots analysis showed a
significant reduction of EGF mRNA expression of approxi-
mately one- to twofold in the renal medulla of HIV-Tg26
mice with early and late RD when compared with WT
control littermate mice (Figure 6b). In a similar manner, the
collagenolytic activity of MMP-9 and MMP-2 was increased
in the urine of HIV-Tg26 mice with RD by an average of
10- to 50-fold, relative to WT and HIV-Tg26 mice without RD
(Figure 6c). Finally, in an earlier study, we found a significant
accumulation of FGF-2 in the kidney of HIV-Tg26 mice with
RD in association with the presence of the tubular
microcystic lesions characteristic of HIVAN.9 Taken together,
all these findings strongly suggest that the urinary profile of
EGF, MMP-2, and FGF-2 changes in correlation to the
progression of the renal tubulointerstitial and microcystic
lesions characteristic of HIVAN.
DISCUSSION
Childhood HIV-associated nephropathy is characterized by
the presence of mesangial hyperplasia and/or focal segmental
glomerulosclerosis in association with the microcystic
transformation of renal tubules and rapid progression of
the RD.1–3 Earlier studies have shown that cytokines play a
role in the development of these renal lesions.21–24 In the
present study, we found a reduced excretion of EGF in the
urine of children with HIV-RD in association with increased
urinary levels of FGF-2 and MMP-2, when compared with
HIV-positive or -negative children without RD. Overall, six
out of seven children of all ages with biopsy-proven HIVAN
showed abnormal urinary values of all three candidate
biomarkers in samples collected when their blood urea
nitrogen and serum creatinine levels were still within the
normal range. In contrast, none of the HIV-positive or
-negative control children without RD or trace proteinuria
showed abnormal urinary levels for all three candidate
biomarkers. These findings suggest that the urinary profile of
EGF, FGF-2, and MMP-2 may allow the identification of
children at high risk of developing HIVAN.
Both EGF and FGF-2 are powerful mitogenic growth
factors for renal tubular epithelial cells.14–20 They play
important roles during renal development and in the
pathogenesis of renal cystic disorders. EGF is predominately
synthesized by renal tubular epithelial cells,14–17 and in the
presence of renal tubular injury, its synthesis and release into
the tubular lumen is expected to decrease. This notion is
supported by the findings in HIV-Tg26 mice with RD, which
showed a significant reduction in EGF mRNA expression in
correlation with the presence of renal tubular injury and
progression of the RD. A similar global reduction of mRNA
and protein EGF expression was found by Horikoshi et al.14
in mice with polycystic kidney disease (cpk). EGF is needed
for the normal growth and regeneration of renal epithelial
cells,14–17 and we have confirmed that EGF present in the
urine of HIV-infected children can stimulate the growth of
cultured human renal tubular epithelial cells. However, as
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Figure 6 | Representative changes in EGF and MMPs activity in
HIV-Tg26 mice. Urine and kidney samples were harvested in a
sequential manner at 10, 25, and 60 days of life from wild-type
(WT) and HIV-Tg26 (HIV) mice with and without renal disease
(n¼ 4 per group). Panel a shows a representative EGF
displacement binding assay in cultured A431 cells exposed to
125I-EGF in the presence of one of the following: recombinant EGF,
urine from WT control mice (U-CTRL), or urine from HIV-Tg mice
with renal disease (U-Tg). Panel b shows a representative northern
blot analysis corresponding to the EGF and the S14 control probes
in the renal medulla from WT and HIV-Tg26 control mice (HIV-C),
and HIV-Tg26 mice with renal disease (HIV-RD). Panel c shows a
representative experiment showing the collagenolytic activity of
urine samples harvested from WT and HIV-Tg26 control mice (HIV-
C), and HIV-Tg26 mice with RD (HIV-RD). The collagenolytic activity
was assessed by gelatin zymography as described in the Materials
and Methods section (c). These experiments were repeated three
times with similar results.
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antibodies against EGF were unable to suppress the complete
mitogenic activity of the urine samples harvested from
children with HIVAN, other growth factors present in
these urine samples (that is, FGF-2) might play a synergistic
role with EGF in this process.6–9 In summary, taken in
consideration all these findings, we propose that the
progressive reduction in the urinary levels of EGF in
HIV-infected children with RD reflect the presence of diffuse
renal tubular injury characteristic of childhood HIVAN. In
support of this notion, we have found that at least three
markers of tubular injury, cystatin C, g-glutamyl transpepti-
dase, and lysozyme, were elevated in the urine of patients
with RD in correlation with the decreased EGF levels.
Fibroblast growth factor-2 is a heparin-binding growth
factor that lacks a classic signal peptide for secretion, but is
released into the circulation by non-conventional pathways
and injured endothelial cells.3,6–9,25 In an earlier study, we
found elevated levels of FGF-2 in the plasma of children with
HIVAN.6 In addition, we found an upregulation of heparan
sulfate proteoglycans in the kidney of HIV-infected children
and HIV-Tg26 mice with RD.
6–9 Thus, renal heparan sulfate
proteoglycans may act as a sink trapping FGF-2 and other
heparin-binding growth factors from the circulation. In
addition, renal tubular epithelial cells harvested from the
urine of children with HIVAN produce and release high levels
of FGF-2, as well as an FGF-binding protein, that facilitates
the release of several members of the FGF’s family, including
FGF-2.7,8 These findings may explain the elevated levels of
urinary FGF-2 in children with HIVAN. In support of this
notion, HIV-Tg26 kidneys with RD show a significant
accumulation of FGF-2 and FGF binding protein-1 in
parallel binding protein1 in parallel with the decreased renal
production of EGF mRNA and development of renal
microcysts.8,9 We have earlier found that FGF-2 induces the
proliferation of human renal epithelial and mesangial cells
harvested from HIV-infected children,6 and systemic infu-
sions of FGF-2 into rodents and monkeys induce mesangial
hyperplasia, FGFS and/or microcystic transformation of renal
tubules.26–31 In summary, these findings suggest that the
accumulation of FGF-2 in the kidney of HIV-infected
children may constitute a risk factor for the development
of HIVAN.
Matrix metalloproteinases are metal-dependent enzymes
that participate in the remodeling of extracellular matrix.12,13
In the kidney, the migration and transdifferentiation of renal
tubular epithelial cells and fibroblasts is at least partially
mediated by the proteolytic activity of MMPs, which degrade
the renal basement membranes allowing the release of FGF-2
and the activation of growth factors bound to the
extracellular matrix .11,12,30,31 The activity and excretion of
MMP-2 is increased in a murine model of infantile-type
polycystic kidney disease.12 Moreover, the expression of
MMP-2 in cells harvested from patients with AIDS–Kaposi’s
sarcoma is induced by FGF-2,25 and increased levels of MMP-
2 and FGF-2 are found in the urine of patients with
AIDS–Kaposi’s sarcoma or polycystic kidney diseases.31–33
Given the extent of renal tissue remodeling and microcystic
changes in children with HIVAN, we speculate that FGF-2
and MMPs may play a similar role in the pathogenesis of
HIV-RD. In support of this notion, we have found a
consistent elevation of MMP-2 protein and activity in the
urine of HIV-infected children with HIVAN and HIV-Tg26
mice in correlation with the accumulation of FGF-2 and
progression of the RD. Taken together, these findings may
explain the synergistic increase in urinary FGF-2 and MMP-2
in children with HIVAN.
We also found elevated levels of MMP-2 and/or MMP-9 in
a few HIV-infected children without proteinuria. These
findings are consistent with the results of other studies
showing that both MMP-2 and MMP-9 can be detected in
the urine of healthy children, probably in connection to the
process of normal tissue growth and remodeling.34 However,
the changes in MMP-2 activity seen in children with HIVAN
can be clearly differentiated from all the other seen HIV-
infected patients. Of interest, earlier studies have shown that
protease inhibitors can inhibit the activity of MMP-2 by
blocking the conversion from its latent to the active
form.35–37 On the basis of these data, we speculate that these
drugs could have a potential beneficial effect in children with
HIV-RD by blocking the activation of MMP-2.
In conclusion, urinary levels of EGF, FGF-2, and MMP-2
might be useful to identify HIV-infected children undergoing
the renal tubular interstitial and microcystic lesions
characteristic of childhood HIVAN. It remains to be
determined whether this urinary growth factor profile is
specific for childhood HIVAN, or could be also found in
HIV-infected children with other RD. A large multicenter
clinical study will be needed to answer this question.
Nevertheless, urinary biomarkers acquire their clinical
value when interpreted in the appropriate clinical context.
African-American children with HIVAN typically show
enlarged echogenic kidneys and isolated proteinuria, which
is responsive to HAART, in the absence of early-onset
hypertension, hematuria, generalized edema, or acute
renal failure.1–3 We have presented evidence that the
urinary levels of EGF, FGF-2, and MMP-2 can also change
in response to HAART. In contrast, other RD seen in
HIV-infected children are less responsive to HAART and can
be suspected by their clinical history and symptoms, the
urinalysis, ultrasound findings, and considering their re-
sponse to antihypertensive drugs or steroids.2 In summary,
we propose that if the urinary EGF, FGF-2, and MMP-2
profile is interpreted in the appropriate clinical context, it
will facilitate the early identification of children at high risk
of developing HIVAN.
MATERIALS AND METHODS
Patients
Urine samples were collected from HIV-negative children (n¼ 28)
and HIV-infected children (n¼ 56) who received regular clinical
care at the Children’s National Medical Center (CNMC) during the
period between January 1995 and December 2008. The study
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protocol and consenting documents were approved by the CNMC’s
IRB. All HIV-infected patients acquired HIV-1 from their mothers
through vertical transmission, with the exception of one child who
was infected through a blood transfusion in the perinatal period.
Children ranged in age from 3 months to 19 years with an
approximately equal rate between male and females. Approximately
94% of all children were African Americans, whereas the remaining
patients were Caucasians, Asians, and Hispanics. The diagnosis of
HIV-infection and AIDS was based on the criteria established by the
Center for Disease Control (CDC).4 The HIV-infected patients were
in the following CDC clinical categories: asymptomatic-A (B4%);
mildly symptomatic-B (B52%), and severely symptomatic-C
(B44%). All children received standard pediatric doses of
antiretroviral therapy under the supervision of attending physicians
with expertise in the treatment of HIV-infected children. The viral
load (HIV-1 RNA PCR) was measured using standard laboratory
assays at least every 6 months as part of routine clinical care.
In seven patients (one childo2 years, and six children42 years of
age), the diagnosis of HIVAN was confirmed by renal biopsy. In two
additional patients, the diagnosis of HIVAN was based on the
following clinical findings: (1) presence of protein creatinine ratios
40.2 mg/mg for more than 6 months; (2) enlarged echogenic kidneys
with a typical clinical history of HIVAN; and (3) development of
chronic renal failure during the longitudinal follow-up period. With
the exception of one child, all urine samples harvested from children
with HIVAN were collected when the blood urea nitrogen and serum
creatinine levels were within the normal range. All samples were stored
immediately at 701C, and processed whenever indicated.
Urinary markers of renal injury
The urinary protein and creatinine levels were confirmed using
colorimetric assays from Wako Diagnostics (Richmond, VA) and R&D
Systems (Minneapolis, MN), respectively. Cystatin C was measured
using an enzyme-linked immunoabsorbent assay according to the
manufacturer’s instructions (R&D Systems). g-Glutamyl transpeptidase
and alkaline phosphatase were assayed following the procedures
described by Chung et al.38 and adapted to microtiter plates. Lysozyme
was measure as described by Shugar.39 Units of lysozyme/ml were
determined following the Sigma quality control test for lysozyme.
Urinary growth factors and metalloproteinases
Urinary levels of EGF, FGF-2, MMP-2 and -9 were measured by
enzyme-linked immunoabsorbent assay kits following the instruc-
tions of the manufacturer (R&D Systems). Gelatin zymography was
performed with 10% SDS-polyacrylamide gels containing 1 mg/ml
gelatine as described earlier.40 Urine samples were diluted 3:1 with
substrate gel buffer (10% SDS, 4% sucrose, 0.25 M Tris-HCl, pH 6.8,
and 0.1% bromophenol blue) and loaded immediately onto the gel
without boiling.40 After staining the gels with Commassie Blue R-
250, the gelatinolytic activity appeared as white bands of the
corresponding molecular weight. Additional urine samples were
incubated with an MMPs inhibitor 20 mM 1, 10-phenanthroline to
inhibit the activity of MMPs.41 The zymography gels were then
scanned with an Epson EP1670 scanner, Long Beach, CA, USA,
using Adobe Photo Shop and results were expressed in arbitrary
optical density (OD) units as OD/urinary creatinine ratios.
Growth of cultured CV-1 cells
CV-1 cells (American Type Culture Collection, Manassas, VA)42
were seeded at a density of 2.0 102 on 96-well plates, and exposed
to urine samples harvested from HIV-infected children with and
without RD (10% urine diluted in Dulbecco’s modified Eagle’s
medium supplemented with 1% fetal bovine serum and antibiotics
(penicillin G, streptomycin sulfate, and amphotericin B) (Invitro-
gen, Grand Island, NY). To neutralize the activity of EGF in the
urine, selected urine samples were preincubated with 30 mg/ml of
EGF antibody for 1 h at 371C (R&D Systems). After 96 h, cell growth
was measured colorimetrically by absorbance at 490 nm using the
Cell Titer 96 reagent (Promega; Madison, WI).
HIV-Tg26 mice
Human immunodeficiency virus-Tg26 mice carrying a defective
HIV-1 proviral DNA43 were used to confirm our findings. Urine and
kidney samples were harvested in a sequential manner at 10, 25, and
60 days of life (n¼ 4 in each group) from WT littermate and HIV-
Tg26 mice with and without RD. Urinary EGF-like activity was
determined by doing binding displacement assays in cultured A431
cells exposed to 125I-EGF (0.1 mCi/ng, DuPont-New England
Nuclear, Wilmington, DE, USA) as described by Mesri et al.44
Northern blots EGF analysis
Total RNA was harvested from the renal medulla of mice at
specific time points using guanidine-thiocyanate as described by
Chirgwin et al.45 Total RNA (10mg) was electrophoresed through
formaldehyde-agarose gels and transferred to nitrocellulose filters.
The filters were hybridized with the 754 bp (SmaI-PvuII fragment
(bases 2886–3639)) or preproEGF cDNA clone (pmeg10)17 as
described by Horikoshi et al.14 Blots were normalized by probing
for the small ribosomal protein S14 (American Type Culture
Collection, plasmid no. 59247) as described earlier.46 The collage-
nolytic activity of urine samples harvested from mice of 10, 25, and
60 days of age was assessed by gelatin zymography and quantified as
described above.
Statistical analysis
Comparison between two groups was done with the Student t-test.
P-values less than 0.05 were considered significant. When more than
two means were compared, significance was determined by one way
analysis of variance followed by multiple comparisons using the
Student–Neuman–Keul’s post hoc test. Non-normal data were either log-
transformed before analysis or analyzed by the Kruskal–Wallis analysis
of variance followed by Dunn’s multiple comparisons post-test.
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